Male Breast Cancer — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Use tamoxifen, considering a GnRH analogue when recurrence risk is higher
Tamoxifen is the standard adjuvant endocrine therapy for hormone-receptor-positive male breast cancer, with a GnRH analogue considered in higher-risk cases. Aromatase inhibitor monotherapy does not adequately suppress testicular oestrogen production, and neither fulvestrant nor orchidectomy is the routine adjuvant standard.
Reference: ESMO Clinical Practice Guideline: breast cancer. https://data.esmo.org/guidelines/pdf/publicassets/ESMO_2023_BreastCancer.pdf